Author(s): Feng Y; Zhen C; Li W; Whiteway M; Fang X; Shen X; Jiang Y; Lu H;

Human body temperature has been shown to limit the antifungal efficacy of azoles; however, the precise mechanisms underlying this limitation remain insufficiently understood. In this study, we observed that short-term exposure (24 h) to human body temperature (37 °C), in contrast to 30 °C, significantly enhances the tolerance of Candida albicans to azoles ...

Article GUID: 42361441

Author(s): Li W; Feng Y; Feng Z; Wang L; Whiteway M; Lu H; Jiang Y;

Fluconazole (FLC) is extensively employed for the prophylaxis and treatment of invasive fungal infections (IFIs). However, the fungistatic nature of FLC renders pathogenic fungi capable of developing tolerance towards it. Consequently, converting FLC into a fungicidal agent using adjuvants assumes significance to circumvent FLC resistance and the perpetua ...

Article GUID: 38929106

Author(s): Feng Y; Lu H; Whiteway M; Jiang Y;

Fluconazole (FLC) tolerant phenotypes in Candida species contribute to persistent candidemia and the emergence of FLC resistance. Therefore, making FLC fungicidal and eliminating FLC tolerance are important for treating invasive fungal diseases (IFDs) caused by Candida species. However, the mechanisms of FLC tolerance in Candida species remain to be fully ...

Article GUID: 37918789

Author(s): Lu H; Li W; Whiteway M; Wang H; Zhu S; Ji Z; Feng Y; Yan L; Fang T; Li L; Ni T; Zhang X; Lv Q; Ding Z; Qiu L; Zhang D; Jiang Y;

Fluconazole (FLC) is widely used to prevent and treat invasive fungal infections. However, FLC is a fungistatic agent, allowing clinical FLC-susceptible isolates to tolerate FLC. Making FLC fungicidal in combination with adjuvants is a promising strategy to avoid FLC resistance and eliminate the ...

Article GUID: 36475771